Unraveling cellular pathways contributing to drug-induced liver injury by dynamical modeling

Isoude A Kuijper1, Huan Yang1, Bob Van De Water1

  • 1a Division of Toxicology, Leiden Academic Centre for Drug Research , Leiden University , Leiden , The Netherlands.

Abstract

Insights

Dynamical pathway modeling can predict drug-induced liver injury (DILI) by simulating stress responses. Repurposing existing models offers a promising approach for novel drug safety screening methods.

Area of Science:

  • Pharmacology and Toxicology
  • Computational Biology
  • Systems Biology

Background:

  • Drug-induced liver injury (DILI) presents a significant challenge in drug development due to its unpredictable nature.
  • Hepatic adaptive stress response pathways are consistently activated during DILI.
  • Current methods, including animal trials, often fail to predict DILI accurately.

Purpose of the Study:

  • To review the progress in dynamical modeling of stress and death pathways relevant to DILI.
  • To explore the application of ordinary differential equation (ODE) modeling for understanding DILI mechanisms.
  • To discuss the adaptation of existing pathway models for DILI research.

Main Methods:

  • Review of existing literature on dynamical modeling of cellular stress pathways.
  • Analysis of ODE models for pathways including oxidative stress, inflammation, DNA damage, unfolded proteins, heat shock, and apoptosis.
  • Discussion on the requirements for applying these models to liver-specific DILI prediction.

Main Results:

  • Significant advancements have been made in modeling cellular stress pathways since 2000.
  • Models of stress pathways have been rarely applied specifically to DILI dynamics.
  • Existing models can often be repurposed for DILI research with parameter adjustments.

Conclusions:

  • Dynamical pathway modeling holds potential for predicting adverse drug effects before clinical trials.
  • Repurposing existing stress pathway models can accelerate DILI research.
  • Integrating dynamical models with in vitro testing may yield novel screening methods for drug-induced toxicity.

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
367
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
82
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
312
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
68
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59